• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FitLife Brands Announces Third Quarter 2023 Results

    11/13/23 7:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $FTLF alert in real time by email

    Omaha, NE, Nov. 13, 2023 (GLOBE NEWSWIRE) -- November 13, 2023 – FitLife Brands, Inc. ("FitLife," the "Company," or "we") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the third quarter ended September 30, 2023.

    Highlights for the third quarter ended September 30, 2023 include:

    • Total revenue was $13.9 million, an increase of 67% compared to the third quarter of 2022. 
    • Adjusted EBITDA was $2.5 million, an increase of 36% compared to the third quarter of 2022.
    • Net income for the third quarter of 2023 was $1.7 million compared to $1.2 million during the same period last year, an increase of 39%.
    • Basic earnings per share increased from $0.27 to $0.38 and fully diluted earnings per share increased from $0.24 to $0.35, an increase of 41% and 46%, respectively.
    • Online revenue accounted for 68% of the Company's total revenue during the third quarter of 2023 compared to 26% during the same period last year.
    • Gross margin was 41.0% compared to 39.0% during the third quarter of 2022. 
    • The Company ended the quarter with $11.3 million outstanding on its term loan and cash of $8.3 million, or total net debt of $3.0 million.

    Financial Performance

    For the third quarter ended September 30, 2023, total revenue was $13.9 million, an increase of 67% compared to $8.3 million during the same period last year.  Online revenue for the quarter was $9.4 million, an increase of 338% compared to the quarter ended September 30, 2022.  Online revenue accounted for 68% and 26% of the Company's total revenue during the quarters ended September 30, 2023 and 2022, respectively.

    Gross margin for the quarter ended September 30, 2023 was 41.0% compared to 39.0% during the same period in the prior year.  The increase in gross margin is primarily attributable to higher online sales compared to the third quarter of 2022.

    The effective tax rate for the quarter ended September 30, 2023 was 20.4%.  A substantial portion of the reported GAAP income tax provision is non-cash due to ongoing utilization of the Company's net operating loss carryforwards.

    Net income for the third quarter of 2023 was $1.7 million, an increase of 39% compared to $1.2 million during the quarter ended September 30, 2022.  Basic earnings per share for the quarter ended September 30, 2023 was $0.38, an increase of 41% compared to $0.27 during the same period in 2022.  Diluted earnings per share increased 46% during the third quarter of 2023 to $0.35 compared to $0.24 last year.

    Adjusted EBITDA for the quarter ended September 30, 2023 was $2.5 million, an increase of 36% compared to the same period in 2022.  The Company ended the quarter with $11.3 million outstanding on its term loan and cash of $8.3 million, or total net debt of $3.0 million. 

    MRC Integration and Operational Improvements

    The Company continues to focus on improving cash flow and profitability at Mimi's Rock Corp ("MRC").  Since acquiring MRC on February 28, 2023, we have focused primarily on improving profitability through cost reductions.  Specifically, we have eliminated over $1.5 million of annual non-advertising SG&A expense (all numbers in this press release are reported in USD and not CAD).

    Separately, we continue to evaluate the effectiveness of MRC's advertising spend.  As previously reported, during the second quarter of 2023 we reduced MRC's advertising expense by 20% compared to the second quarter of 2022 with no material impact on revenue.

    We experimented with further reductions during the third quarter of 2023, reducing advertising expense by approximately 30% compared to the same quarter in 2022.  Although the additional reduction in advertising expenditure resulted in approximately 8% lower revenue, it increased contribution (defined as gross profit minus advertising expense) by approximately 15%.  In other words, through these actions, the Company is increasing its profitability by eliminating unprofitable revenue. 

    As a result of our efforts, MRC advertising expense during the third quarter of 2023 was 16.6% of MRC revenue, compared to 21.9% during the same quarter in the prior year, a quarterly impact of over $0.5 million or an annualized impact of approximately $2.1 million.  With these changes, MRC's profitability has increased significantly since the acquisition, accounting for approximately 69% of the Company's reported net income for the third quarter of 2023.

    Going forward, we intend to continue to closely monitor and optimize advertising expenditures, increasing spending on effective campaigns while reducing spending on ineffective campaigns.  As a result, advertising expense may increase or decrease in the future.

    Legacy FitLife Performance

    During the third quarter of 2023, legacy FitLife revenue declined 19%, driven by a 27% decline in wholesale revenue partially offset by an 8% increase in online revenue. 

    Due to the size and timing of wholesale orders, wholesale revenue recognized by the Company during a quarter is not necessarily reflective of the retail demand for the Company's products.  During the quarter ended September 30, 2023, based on data shared by our wholesale partners, the retail movement of the Company's products through wholesale channels declined approximately 14%.  The Company is exploring new international wholesale opportunities for some of its legacy FitLife brands that are expected to at least partially offset the declines being experienced in the U.S.

    While still positive, the growth rate for legacy FitLife's online revenue declined over the first eight months of the year.  The declines were driven primarily by a combination of fewer consumer sessions as well as underperformance of certain brands and products.  Although session counts have declined, indicating lower traffic on our online listings, conversion rates have generally increased during the year, partially offsetting the decline in sessions. 

    The year-over-year growth rate was lowest during August before improving sequentially in September and again in October.  Thus far in November, the year-over-year growth rate has continued to show sequential improvement.  During the third quarter of 2023, subscriptions accounted for approximately 23% of legacy FitLife's online sales volumes.

    Acquisition of MusclePharm Assets

    As previously reported, the Company successfully closed the acquisition of substantially all of the assets of MusclePharm Corporation ("MusclePharm"), which primarily consisted of intangible assets.  None of the liabilities of MusclePharm were assumed other than de minimus cure costs relating to certain assumed contracts.  Total consideration for the acquisition was approximately $18.5 million cash.  Of this amount, $10.0 million was funded using proceeds from a new term loan provided by First Citizens Bank, with the remainder funded from FitLife's available cash balances. 

    Since closing the acquisition, management has begun engaging in discussions with several of MusclePharm's previous customers in an effort to restore wholesale distribution of the brand.  The Company is also in the process of re-launching some historically successful MusclePharm products. 

    Online sales of MusclePharm products are expected to be limited in the fourth quarter while third-party resellers deplete their inventory.  As these resellers run out of product, the Company will become the primary seller of MusclePharm products online.  We expect online revenue from MusclePharm products to exceed $5 million in 2024.

    Dayton Judd, FitLife's Chairman and CEO, commented, "Although the third and fourth quarters of each year are traditionally the slowest for the Company, I am pleased with our overall performance.  While recent legacy FitLife performance has not met expectations, the weakness has been largely offset by strong financial performance at MRC.  Going forward, I am optimistic that legacy FitLife performance will improve, and I am excited about the continued improvements at MRC as well as the potential of the MusclePharm brand to create additional stockholder value."

    About FitLife Brands

    FitLife Brands is a developer and marketer of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers.  FitLife markets over 240 different products primarily online, but also through domestic and international GNC® franchise locations as well as through more than 17,000 additional domestic retail locations.  FitLife is headquartered in Omaha, Nebraska.  For more information, please visit our website at www.fitlifebrands.com.

    Forward-Looking Statements

    Statements in this release that are forward looking involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to be materially different from any future performance that may be suggested in this news release.  Such factors may include, but are not limited to, the ability of the Company to continue to grow revenue, the Company's ability to successfully integrate acquisitions, and the Company's ability to continue to achieve positive cash flow given the Company's existing and anticipated operating and other costs.  Many of these risks and uncertainties are beyond the Company's control.  Reference is made to the discussion of risk factors detailed in the Company's filings with the Securities and Exchange Commission including its reports on Form 10-K and 10-Q.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.

    Non-GAAP Financial Measures 

      

    The financial presentation below contains certain financial measures defined as "non-GAAP financial measures" by the SEC, including non-GAAP EBITDA and adjusted non-GAAP EBITDA. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. 

      

    As presented herein, non-GAAP EBITDA excludes interest, foreign exchange gains and losses, income taxes, and depreciation and amortization. Adjusted non-GAAP EBITDA excludes, in addition to interest, taxes, depreciation and amortization, equity-based compensation, M&A/integration activities, restatement related expense and non-recurring gains or losses. The Company believes the non-GAAP measures provide useful information to both management and investors by excluding certain expense and other items that may not be indicative of its core operating results and business outlook. The Company believes that the inclusion of non-GAAP measures in the financial presentation herein allows investors to compare the Company's financial results with the Company's historical financial results and is an important measure of the Company's comparative financial performance. 

    FITLIFE BRANDS, INC.
    CONDENSED CONSOLIDATED BALANCE SHEETS
    (In thousands, except per share data)
         
      September 30, December 31,
      2023 2022
      (Unaudited)  
    ASSETS:    
    CURRENT ASSETS    
    Cash and cash equivalents $7,343 $13,277
    Restricted cash 969 -
    Accounts receivable, net of allowance of doubtful accounts of $33 and $50, respectively 1,428 705
    Inventories, net of allowance for obsolescence of $142 and $107, respectively 7,724 9,105
    Sales tax receivable 1,276 -
    Prepaid expenses and other current assets 787 116
    Total current assets 19,527 23,203
         
    Deposit for MusclePharm asset acquisition 1,825 -
    Property and equipment, net 199 46
    Right of use asset 141 103
    Intangibles, net of amortization of $103 and $72, respectively (provisional) 7,746 150
    Goodwill (provisional) 13,321 358
    Deferred tax asset 1,213 1,847
    TOTAL ASSETS $43,972 $25,707
         
    LIABILITIES AND STOCKHOLDERS' EQUITY:    
    CURRENT LIABILITIES:    
    Accounts payable $2,379 $2,995
    Accrued expense and other liabilities 1,828 631
    Product returns 587 590
    Term loan - current portion 2,500 -
    Lease liability - current portion 94 54
    Total current liabilities 7,388 4,270
         
    Term loan, net of current portion 8,750 -
    Long-term lease liability, net of current portion 59 49
    Deferred tax liability 2,526 -
    TOTAL LIABILITIES 18,723 4,319
         
    STOCKHOLDERS' EQUITY:    
    Preferred stock, $0.01 par value, 10,000 shares authorized, none outstanding    
    as of September 30, 2023 and December 31, 2022 - -
    Common stock, $0.01 par value, 60,000 shares authorized; 4,446 and 4,507    
    issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 44 45
    Additional paid-in capital 30,151 30,056
    Accumulated deficit (4,897) (8,713)
    Foreign currency translation adjustment (49) -
    TOTAL STOCKHOLDERS' EQUITY 25,249 21,388
         
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $43,972 $25,707
         





    FITLIFE BRANDS, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
    (In thousands, except per share data)
    (Unaudited)
             
      Three months ended Nine months ended
      September 30,  September 30, 
      2023 2022 2023 2022
             
             
    Revenue $13,902 $8,314 $39,401 $23,433
    Cost of goods sold 8,206 5,070 23,332 13,587
    Gross profit 5,696 3,244 16,069 9,846
             
    OPERATING EXPENSES:        
    Selling, general and administrative 3,172 1,680 8,758 4,620
    Merger and acquisition related expense 32 6 1,519 214
    Depreciation and amortization 22 17 64 49
    Total operating expenses 3,226 1,703 10,341 4,883
             
    OPERATING INCOME 2,470 1,541 5,728 4,963
             
    OTHER EXPENSES (INCOME)        
    Interest income (119) (43) (269) (59)
    Interest expense 249 - 598 -
    Foreign exchange loss 210 - 93 -
    Total other (income) expense 340 (43) 422 (59)
             
    NET INCOME BEFORE INCOME TAX PROVISION 2,130 1,584 5,306 5,022
             
    PROVISION FOR INCOME TAXES 434 364 1,490 1,066
             
    NET INCOME $1,696 $1,220 $3,816 $3,956
             
    NET INCOME PER SHARE        
    Basic $0.38 $0.27 $0.86 $0.87
    Diluted $0.35 $0.24 $0.78 $0.79
    Basic weighted average common shares 4,446 4,556 4,458 4,555
    Diluted weighted average common shares 4,891 4,988 4,901 4,979
             





     FITLIFE BRANDS, INC. 
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
    FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
    (In thousands)
    (Unaudited)
         
      Nine months ended September 30, Nine months ended September 30,
      2023 2022
         
    CASH FLOWS FROM OPERATING ACTIVITIES:    
    Net income $3,816 $3,956
    Adjustments to reconcile net income to net cash provided by operating activities:    
    Depreciation and amortization 64 49
    Allowance for doubtful accounts (17) (5)
    Allowance for inventory obsolescence 35 147
    Stock compensation expense 94 295
         
    Changes in operating assets and liabilities:    
    Accounts receivable - trade (498) (585)
    Inventories 2,534 (1,205)
    Deferred tax asset 709 1,053
    Prepaid expenses and other assets (463) 93
    Right of use asset 60 41
    Accounts payable (3,570) 1,086
    Lease liability (60) (41)
    Product returns (3) (15)
    Accrued liabilities and other liabilities 71 134
         
    Net cash provided by operating activities 2,772 5,003
         
    CASH FLOWS FROM INVESTING ACTIVITIES:    
    Purchase of property and equipment (60) -
    Cash paid for acquisition of Mimi's Rock Corp. (17,099) -
    Cash deposit paid for the acquisition of assets (1,825) -
    Net cash used in investing activities (18,984) -
         
    CASH FLOWS FROM FINANCING ACTIVITIES:    
    Proceeds from exercise of stock options - 29
    Borrowings on term loan 12,500 -
    Payments on term loan (1,250) -
    Net cash provided by financing activities 11,250 29
         
    Foreign currency impact on cash (3) -
         
    CHANGE IN CASH AND RESTRICTED CASH (4,965) 5,032
    CASH, BEGINNING OF PERIOD 13,277 9,897
    CASH AND RESTRICTED CASH, END OF PERIOD $8,312 $14,929
         





      For the three months ended

    September 30,
     For the nine months ended

    September 30,
      2023 2022 2023 2022
      (Unaudited) (Unaudited) (Unaudited) (Unaudited)
    Net Income $             1,696 $         1,220 $             3,816 $         3,956
    Interest expense                   249                    -                     598                 -  
    Interest income                  (119)               (43)                  (269)               (59)
    Foreign exchange loss                   210                 -                       93                 -  
    Provision for income taxes                   434              364                1,490            1,066
    Depreciation and amortization                     22                17                     64                49
    EBITDA                2,492            1,558                5,792            5,012
    Non-cash and non-recurring adjustments        
    Stock compensation expense                     21               91                     94              295
    Merger and acquisition related costs                    32                  6                1,519              214
    Amortization of inventory step-up                     -                     -                     323                 -  
    Non-recurring loss on foreign currency forward                     -                   -                     112                 -  
    Restatement related costs                     -                220                     -                275
    Adjusted EBITDA $             2,545 $         1,875 $             7,840 $         5,796
             


    [email protected]

    Primary Logo

    Get the next $FTLF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTLF

    DatePrice TargetRatingAnalyst
    3/17/2025$21.00Buy
    Lake Street
    9/3/2024$40.00Buy
    ROTH MKM
    More analyst ratings

    $FTLF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on FitLife Brands with a new price target

    Lake Street initiated coverage of FitLife Brands with a rating of Buy and set a new price target of $21.00

    3/17/25 8:22:47 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    ROTH MKM initiated coverage on FitLife Brands with a new price target

    ROTH MKM initiated coverage of FitLife Brands with a rating of Buy and set a new price target of $40.00

    9/3/24 7:48:49 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    $FTLF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FitLife Brands Announces Third Quarter 2025 Results

    OMAHA, NE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the third quarter ended September 30, 2025. Highlights for the third quarter ended September 30, 2025 include: On August 8, 2025, the Company completed the acquisition of substantially all of the assets of Irwin Naturals ("Irwin"), and Irwin's operating results for the period of August 9 through September 30 are included in FitLife's consolidated financials for the third quarter of 2025.Total revenue was $23.5 million, an increase of 47% compared to the th

    11/13/25 7:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    FitLife Brands Announces Third Quarter Earnings Call

    OMAHA, NE, Nov. 07, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife," or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it plans to report its financial performance for the third quarter of fiscal 2025 on Thursday, November 13, 2025. In addition, the Company announced that it will hold an investor conference call after market close on November 13, 2025 at 4:30 pm ET.  Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 811541.  International participants can dial (973) 528-0163 and provide the same co

    11/7/25 4:00:00 PM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    FitLife Brands Announces Second Quarter 2025 Results

    OMAHA, NE, Aug. 14, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the second quarter ended June 30, 2025. Highlights for the second quarter ended June 30, 2025 include: Total revenue was $16.1 million, 5% lower than the second quarter of 2024.  Online revenue was $10.4 million, representing 65% of total revenue and down 7% compared to the second quarter of 2024.Gross margin was 42.8% compared to 44.8% during the second quarter of 2024.Net income for the second quarter of 2025 was $1.7 million compared to $2.6 million dur

    8/14/25 7:00:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    $FTLF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ordal Todd bought $3,621 worth of shares (300 units at $12.07), increasing direct ownership by 0.48% to 62,488 units (SEC Form 4)

    4 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

    4/16/25 8:00:07 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Lingenbrink Matthew bought $36,510 worth of shares (3,000 units at $12.17), increasing direct ownership by 107% to 5,800 units (SEC Form 4)

    4 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

    4/16/25 8:00:05 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Lingenbrink Matthew bought $34,089 worth of shares (2,800 units at $12.17) (SEC Form 4)

    4 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

    4/2/25 8:01:06 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    $FTLF
    SEC Filings

    View All

    FitLife Brands Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FITLIFE BRANDS, INC. (0001374328) (Filer)

    12/10/25 8:02:12 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    FitLife Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FITLIFE BRANDS, INC. (0001374328) (Filer)

    11/13/25 7:45:16 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by FitLife Brands Inc.

    10-Q - FITLIFE BRANDS, INC. (0001374328) (Filer)

    11/13/25 7:30:53 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    $FTLF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF FINANCIAL OFFICER York Jakob

    4 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

    9/8/25 10:19:11 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    New insider Hansen Ryan P. claimed ownership of 25,678 shares (SEC Form 3)

    3 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

    5/12/25 7:27:11 PM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Pappas Shannon K.

    3 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

    5/12/25 7:26:27 PM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    $FTLF
    Leadership Updates

    Live Leadership Updates

    View All

    FitLife Brands Announces Board Transition

    Omaha, NE, April 28, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, announced today the resignation of Todd Ordal as a member of the Company's Board of Directors. Mr. Ordal's resignation, effective on April 25, 2025, was part of the Company's ongoing commitment to refresh board composition on a regular basis in accordance with good corporate governance practices and was not the result of any disagreement with the Company's management or the Board of Directors regarding any matter related to the Company or otherwise. On April 25, 2025, the Board of Directors of

    4/28/25 7:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    LifeVantage Appoints Dayton Judd to the Board of Directors

    SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Dayton Judd to the Company's Board of Directors (the "Board"), effective immediately, in an expansion of the Board. The Company has had discussions with Bradley L. Radoff and Sudbury Capital Fund, LP (collectively with certain of their affiliates, the "Radoff-Sudbury Group"), which owns approximately 12.6% of the Company's outstanding stock, since the Company's fiscal year 2024 annual meeting of shareholders held on November 6, 2023. During these dis

    2/15/24 4:05:00 PM ET
    $FTLF
    $LFVN
    $OPXS
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Electronic Components

    $FTLF
    Financials

    Live finance-specific insights

    View All

    FitLife Brands Announces Third Quarter 2025 Results

    OMAHA, NE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the third quarter ended September 30, 2025. Highlights for the third quarter ended September 30, 2025 include: On August 8, 2025, the Company completed the acquisition of substantially all of the assets of Irwin Naturals ("Irwin"), and Irwin's operating results for the period of August 9 through September 30 are included in FitLife's consolidated financials for the third quarter of 2025.Total revenue was $23.5 million, an increase of 47% compared to the th

    11/13/25 7:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    FitLife Brands Announces Third Quarter Earnings Call

    OMAHA, NE, Nov. 07, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife," or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it plans to report its financial performance for the third quarter of fiscal 2025 on Thursday, November 13, 2025. In addition, the Company announced that it will hold an investor conference call after market close on November 13, 2025 at 4:30 pm ET.  Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 811541.  International participants can dial (973) 528-0163 and provide the same co

    11/7/25 4:00:00 PM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    FitLife Brands Announces Second Quarter 2025 Results

    OMAHA, NE, Aug. 14, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the second quarter ended June 30, 2025. Highlights for the second quarter ended June 30, 2025 include: Total revenue was $16.1 million, 5% lower than the second quarter of 2024.  Online revenue was $10.4 million, representing 65% of total revenue and down 7% compared to the second quarter of 2024.Gross margin was 42.8% compared to 44.8% during the second quarter of 2024.Net income for the second quarter of 2025 was $1.7 million compared to $2.6 million dur

    8/14/25 7:00:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care